obinutuzumab
roche,biogen,nippon shinyaku
['dlbcl', 'obinutuzumab']
fellow dr. jeff cherng shares how ctdna helped identify patients with newly diagnosed dlbcl who would benefit from lenalidomide and obinutuzumab with chop. watch to see him present abstract 7553 and read the full data here: #asco22 
The official account of MD Anderson Cancer Center, a leader in cancer care, cancer research and the fight to #EndCancer. Appointments available: 1-877-632-6789.